SUMMARY A method for the detection of total, type I, and type II intrinsic factor antibodies was devised. The technique comprises a two-site solid phase enzyme linked immunosorbent assay (ELISA), with human intrinsic factor conjugated with horseradish peroxidase as label and attached to polystyrene tubes as solid phase. One conjugation provides sufficient material to assay more than 10 000 patient samples. The label proved stable during the course ofthis evaluation and was still in use more than 12 months after preparation. When applied to 45 serum samples from cases of pernicious anaemia, intrinsic factor antibodies were shown in 30 (67%). Simplicity, high capacity, low cost and label stability, combined with relatively high clinical sensitivity make the method suitable for cost effective screening of large numbers of samples. Simple modifications to the basic assay reagents permitted type I and type II intrinsic factor antibodies to be differentiated.
Despite being available for almost 30 years,' application of tests for circulating antibodies to gastric intrinsic factor has been limited, because the tests have not been readily available to all routine laboratories, and secondly, they have been capable of showing the presence of antibodies in only about 50% of patients with pernicious anaemia. It has been proposed, however, that the demonstration of intrinsic factor antibodies in patients with megaloblastic anaemia and low serum vitamin B12 concentrations could be regarded as diagnostic ofpernicious anaemia and may avoid the need for B12 absorption tests. 2 Two types of intrinsic factor antibody are known to exist,3 one ofwhich reacts with the intrinsic factor-B12 binding site (type I); the other (type II) detects an antigen site unrelated to the B12 binding activity. Methods of detection have concentrated on type I, making use ofthe ability ofthe antibody to prevent the uptake of 57Co-B12 by intrinsic factor, combined with a charcoal separation procedure.' Recently, a method that used 1251-labelled intrinsic factor has been described: this focuses on the ability of the antibody to bind to intrinsic factor directly' instead of showing a type I antibody blocking effect.' This method has also been modified to detect and quantify both type I 
Material and methods

GASTRIC JUICE
A pool of human gastric juice stimulated by pentagastrin was used for the preparation of assay reagents. All individual samples had a pH of less than 1.5 before 308 depepsinisation'°and storage at -20°C. This gastric juice was used as the source of intrinsic factor in the preparation of the solid phase intrinsic factor and enzyme labelled intrinsic factor test reagents.
SOLID PHASE INTRINSIC FACTOR
Polystyrene tubes were coated with intrinsic factor using the glutaraldehyde pre-treatment method of Boenisch." Five hundred microlitres of a 0 1% solution of glutaraldehyde (Sigma Chemical Company Ltd, Poole, Dorset, England) in 0-1 M carbonate/ hydrochloric acid buffer (pH 9 0) were dispensed into 75 mm x 11 mm polystyrene tubes (Sarstedt Ltd, Beaumont Leys, Leicester, England). These were then incubated at 56°C for three hours, washed twice with distilled water, and dried. Two hundred microlitres of ammonium sulphate precipitated human gastric juice" containing 100 ng intrinsic factor were dispensed into all tubes, which were then stored at 4°C until required.
ENZYME LABELLED INTRINSIC FACTOR
Human gastric juice was concentrated by ultrafiltration (Amicon Ltd, Woking, Surrey, England) through a 10 000 molecular weight cut off membrane. Following overnight dialysis against three x one litre changes of0 05 M phosphate buffered saline (PBS), pH 7 4, the preparation was centrifuged at 30 000 x g for 30 minutes and any sediment discarded. The supernatant was further purified by gel filtration on a 50 cm x 2-5 cm column of Sephacryl S200 (Pharmacia Ltd, Central Milton Keynes, Buckinghamshire, England) equilibrated in 0-05 M PBS (pH 7.4). Two main protein peaks (A280) were obtained within 80 fractions, each of 2 ml volume. The intrinsic factor, as measured by the method of Chanarin,4 was located within the second of these peaks. The fractions containing intrinsic factor were then pooled, further concentrated by ultrafiltration as before (Amicon Ltd, Woking, Surrey, England), and divided into 5 ml amounts containing 5 mg of protein before storage at -200C.
A 5 mg portion of the purified gastric juice was conjugated to horseradish peroxidase (Sigma Chemical Company Ltd) by the periodate-aldehyde method of Nakane and Kawoia.'4 The resulting preparation was applied to a 50 cm x 2 5 cm column of Sephacryl S200 (Pharmacia Ltd) equilibrated in 0 05 M PBS (pH 7-4). Fractions of 2 ml volume were collected and the individual absorbances measured at 280 nm (total protein) and 403 nm (horseradish peroxidase). The fractions containing intrinsic factor associated with horseradish peroxidase were pooled. Bovine serum albumin (BSA) was added at a concentration of 10 g/l before being stored in aliquots of 100 pl at -20°C. The requisite number ofpolystyrene tubes coated with intrinsic factor were loaded into numbered centrifuge multitube carriers (MSE Scientific Instruments, Crawley, Sussex, England). From this point all manipulations and timings were carried out within these carriers in strict numerical order. The tubes were washed three times with a 0 05% solution of Tween 20 in distilled water. After the final wash they were briefly centrifuged and aspirated to remove the last drops of wash solution.
One hundred microlitres of the appropriate control or test sample were added. The tubes were centrifuged and incubated at 37°C for 60 minutes. At the end of this time the tubes were again washed three times as before.
Two hundred microlitres of intrinsic factor/horseradish peroxidase conjugate, freshly diluted in buffer B, were then added. The tubes were centrifuged and incubated at 37°C for a further 60 minutes and washed three times.
Five hundred microlitres of freshly prepared substrate were added and the tubes centrifuged, after which the reaction was allowed to proceed in the dark at room temperature for 60 minutes. Reagent blanks containing 500 p1 ofsubstrate alone were treated in the same way. The reaction was stopped by the addition of using each tube batch on four occasions at weekly intervals.
Results
Measured and calculated data for an enzyme labelled intrinsic factor preparation are shown in table 1. An average of2-56 horseradish peroxidase molecules were calculated to be attached to one intrinsic factor molecule. Table 2 shows the mean absorbances and standard deviations obtained using buffer A (non-specific binding) and the negative serum pool. An unpaired Student's t test was performed to investigate differences between the two groups. As shown in the table, no significant difference was shown. Consequently, the results for the negative serum pool were used to establish 95% confidence limits of 0-043 ± 0 03, to indicate the range of absorbances expected for negative intrinsic factor antibody sera. Non-specific binding and negative serum pool responses, expressed as percentages of those obtained for sera from the two cases of intrinsic factor antibody positive pernicious anaemia in the same assay are shown in table 3. The background to signal relation ranged from 5 4% to 13-2%, and the lack of trend in these figures indicates that the assay reagents were stable during the evaluation period.
Figs I and 2 show total, type I, and type II antibody Results obtained by the radioassay and ELISA methods for samples from patient groups 1 and 2 are shown in table 5 . All control sera gave negative results.
Discussion
The method presented was sensitive, of high capacity, and non-isotopic, capable of detecting total, type I, and type II antibodies to human intrinsic factor. Intrinsic factor/enzyme conjugate was prepared by the method of Nakane and Kawaoi. '4 These authors reported that a maximum of five to six horseradish peroxidase molecules may be attached to one IgG molecule and that for immunoassay purposes, conju- gates with a horseradish peroxidase:protein molecular ratio of greater than 1 produced enhanced sensitivity.'417 The optimal ratio quoted was 2-3 horseradish peroxidase: Iprotein molecule. The horseradish peroxidase:intrinsic factor molar ratio of 2-56:1 produced in our first conjugation was in good agreement with this, and in a second conjugation a ratio of 4-0:1 was obtained. The assay reagents were stable over four weeks and we have continued to use the original conjugate label without signs of serious deterioration for more than 12 months.
The sensitivity of the method was confirmed by the low level of non-specific binding and by the fact that no significant difference could be shown between this and the response produced by an intrinsic factor antibody negative serum pool. Dose responses were obtained for total, type I, and type II intrinsic factor antibodies (figs 1 and 2). Total antibody was detectable to a serum dilution of 1/100 in case 1 and 1/1000 in case 2. Although the curve produced by type II antibody reflected the sigmoid shape produced by total antibody in both cases, differences were observed in the responses obtained for type I antibody. For case 1, a positive type I response could be shown to a dilution of 1/2; a positive result was obtained for the 1/4 dilution in case 2. These results are both in agreement with those obtained using the radioassay 4 This was in good agreement with previously reported clinical sensitivity figures for type I intrinsic factor antibody methods.71318 Our ELISA showed increased sensitivity-the proportion of positive reactions rising to 67%. Both methods were specific for pernicious anaemia as no known false positive results were detected in the control group of 80 patients. Two patients in group 1, however, gave discrepant results, one being positive by the radioassay and negative by the ELISA method; the converse being true in the second. Unfortunately, further information was unavailable on these patients and we were unable to reach a conclusive diagnosis. By increasing the serum:intrinsic factor antigen ratio by up to 1000-fold, Nimo and Carmel recently improved the sensitivity of their radioassay method for type I antibody.'9 We intend to investigate the effect of different solid phase intrinsic factor concentrations on the sensitivity of our ELISA system. The intrinsic factor antibody ELISA described here uses a non-isotopic label which has proved stable for a minimum period of 12 months. One enzyme/intrinsic factor conjugation procedure is capable of producing sufficient label to test in excess of 10 000 patient samples. The assay method is quick, results being produced within the working day, and the procedural steps are straightforward. The method is cost effective when compared with other, particularly commercial intrinsic factor, assay methods which cost approximately £3.00 a patient. These factors, combined with increased clinical sensitivity, constitute an ideal method for a screening test in the investigation of B 12 deficiency. The technique has the added potential for the quantitative measurement of type I and type II intrinsic factor antibodies and may contribute to the further understanding of their importance in relation to pernicious anaemia.
We are grateful to Mrs A Tomlin, University department of surgery, Manchester Royal Infirmary, for the collection and supply of gastric juice. Thanks also go to David Hoctor, department of haematology, Manchester Royal Infirmary, and Peter Howell, National Blood Transfusion Service, Manchester, for helpful comments and advice; and to Mrs Beverley Howarth for her secretarial assistance.
